i would buy some spy puts. >> joker, joker. >> and if the market is down a lot in the morning, only in down a little. >> guy? >> i'll teach steve how to play would you rather pause he clearly doesn't know how to play. lost cause. newmont mining. >> see you back here tomorrow. "mad money" starts right now. >> there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. >> hey, i'm cramer. welcome to "mad money." welcome to cramerica. i'm trying to save you. my job is to educate and teach and explain things like today so call me or of course tweet me @jimcramer. never thought i would say this never, but i'm becoming a proud american firster, at least when it comes to your american you

know the american first people. they wanted to keep us out of foreign wars stay home and build a big moat and today a country famous for cuckoo clocks does something cuckoo sending our markets down s&p tumbling and nasdaq plunging 1.48. why do i want to come? let me start with the foreign wars the foreign currency war going on in europe? i don't know where it is this morning. the swiss decided to make the currency stronger versus the euro, one of the necessary but still shocking things that spits land had to do to keep hot money flowing out of euro denominated banks into swiss franc denominated banks. their banks were becoming too much a part of the swiss economy and we've seen that that can lead to disaster, ireland, cypress and ireland.

as much as this was good by the regulateors wanted this its stunned currency traders were wondering the companies that owe swiss bank money may not be able to pay back that money because the currency got strong. scary. now, none of that really matters to me because of my new found american firstism. i almost never talk about currencies because i used to dabble with them in my old hedge fund. let me tell you something. hated their fast paced nature and high risk of enterprise. other people were thrilled with high risk. i didn't like risk. let me give you an example. once i bought millions of dollars of the old dutch gilder on the hunch that the dufrp market would rally. while the trader went about his business buying i stepped out to get a burger king burger and fries at burger king one real close to me. about 24 years ago, and proudly 24 pounds ago. i was having it my way at the

king. a russian coup occurred against gorbachev and traders had their way with me and i lost about $250,000 as all the european currencies collapsed over fears that the communists were back in charge. that was one expensive charbroiled bomb trade as it got crushed against the dollar. i watched the coup failed. next time i said i'm never going to trade currencies again and i'm only going to mcdonald's. that's the kind of thing that can happen when you trade overseas. the big gunslingers guys they come on our air, always doing things like this. going long to pound and short the franc and ganging up on peso and doing all sorts of things and making them sound real smart. maybe they never go out to lunch but the key takeaway is this stuff is inpenetrable to everyone but the pros. trust me.

what's darn point? will greece leave the euro? i don't know gloriously greek to me. i say when in doubt you have to remember what clint eastwood taught us in that tour du force finance movie "magnum force." >> a man's got to know his limitations. >> to me it's exhibit "a" that you want to stay on shore, our own stocks are companies with very little economic sensitivity. that's why i always say, okay repeat after me what's the swiss franc have to do with the priss-to-earnings ratio of brieiersbrie bristol meyers? they aren't laughing out loud. out loud they are laughing. let me tell you what they are thinking. why am i making it so hard hon myself? second to be an american firster, without decease fellow travelers we are doing really well in the country and other places are floundering around

doing a whole lot of nothing. lots of people are waiting to see what the european central bank will do to revive growth. you think i have an idea what they will do? they have real structural problems over there. you think the other people that pontificate about it really know. come on! i want to know how much bleach clorox is going to sell. i can game that. i want to know if the formulation may be spurring the biogens. i can figure that out. i want to beat the other guys to the selgene punch. but trying to figure out what angela merkel aka herbert hoover is doing in a pant suit lecturing poor nations how they should have balanced budgets. beamers that would be too expensive if germany still used the deutsche mark. third reason to be an american firster, have you in the the we're the only country on earth where everything could be blockbustered down the road?

we've been doing the biotech series all week. where are the european biotechs head scratcher, european social media stocks and the cloud computing business and the only one is run by bill mcdermott an american and also proud eagle fans. i know they are working on a jim dandy high sound system. when you make more money domestically you should say domestic. first reason to be an american firster when it comes to stock picker, the more the stock gets the more -- go to the restoration hardware website. they prefer you look at the website. humor me. look at all that stuff from europe. they source it there so you think you're going to cut the price here now that the dollar is so strong. no way. can you imagine the gross margins and the sweet italian fabric? fifth reason to be an american firster. we've got the goods, the natural resources and the brain power and the universities.

i know i sound like jamie dimon who hates the regulators and cursed on a conference call. not my style. the playing field is going our way. why are we going to the other part of the playing field? why go to the bottom? we're not hostage to russia for natural gas? got the cheapest power in the world and bizarrely the most stable government the most rational and tightest central bank. we've got the finest corporate governments, seriously. i mean we do. i'm not kidding, plus best of all we've got lots of guys who speak english! remember, right now the market is being gripped by a horrid mood disorder where big trigger points think it goes down. hate it when interest rates go down. i mean it's like bizarro, we're like ugly and they put the head on a venus de milo over there. like so-called shocks like when a notoriously neutral nation

with mountains and cheese defends the banking business by shocking the banking system with a year long reversal of its philosophy. that means sell, sell sell sell everything. the swiss, i don't even know and now it's horrible. even the stuff that go higher off the manufacturing crisis went lower today. i say, look don't buy, buy, buy. that's way too glib. pick up the mesh first tox that are entirelily domestic and nothing to do with bottom-saving commodities because commodities are not america per se stocks they are china first stocks and there's plenty of domestic business in restaurants, retailers, real estate investment trusts, utilities. i tell them all about it all the time and throw in the biotechs nothing to do with the swiss situation there. here's the bottom line. america first. i've never felt so good. hope one day -- i hope one day you say he kept us out of foreign currency wars and you think not of woodrow wilson but me the president of cramerica. larry in massachusetts.

larry. >> caller: jim happy new year and thanks for keeping us focused when the only bulls are running in pamplona or san miguel. >> yeah, had a nice bull ring right down the block. have to try to tell people to stay focused. when i tell people on twitter to stay focused i really mean you're a really good guy and thank you for tweeting. >> despite this hideous day it seems odd that biopharma is down 8% after a positive presentation at the jpmorgan conference. >> well i mean look there are a lot of them that are presented. what i try to do is pick among the least speculative. i've had -- two that i think are too speculative. we have to understand larry, this is a really speculative stock, and we've got a lot of really fine biotechs getting crushed right now so maybe we can be a little less speculative and more choosey. let's go to enriquey in florida.

enrique. >> caller: hey jim, first time caller. love the show. >> thank you. >> caller: my first question is about a trade for gopro, i'm currently at $62 a share and want to buy more to bring down my price. do you think earnings would move the price up? >> gopro is really good when it had tight float ant wasn't a lot of stock for sale and going into the holiday season and then it was done. i mean it's happened. it happens like that a great trade and we fortunately nabbed a lot of the trade and now we're on to the next like mobile eye, great trade and now we're on to the next and we're on to the next. mark in california. mark? >> caller: hey jim, boo-yah to you. thanks for taking my call. >> no problem. >> caller: got a question. what is going on with sprint? i have some of it. do i hold it or buy more because it's cheap or do i dump it now? >> okay. here's what happened to sprint. people thought that sprint would merge, t-mobile would merge with

sprint but the government that allows cartels, excuse me benign ole goal pollys in railroad and don't mind it in airlines, you're doing a little office products they are find with it but don't like it in telephone. it means sprint stock is a call of what will happen. won't go much higher. it could go higher ultimately a year from now start going higher. listen to me. i am a proud american firster. i want you to use the week just to pick up some of the domestic stocks because boy oh, boy never felt so good to be an american firster, again with the kind of religious overtones. on "mad money" my special series "biotech, the next generation" continues. getting a step closer to helping you protect from ebola. and this blasted up a monster, 340% and it gave back nine

points today. hmm, let's take a look at that one. target is closing up shop in canada after racking up billions in canadian losses. don't miss my take on what this might mean for the future of that once great retail giant. stick with cramer. >> don't miss a second of "mad money." follow @jimcramer on twitter and tweet cramer at #madtweets and send jim an e-mail at madmoney@cnbc.com or give us a call at 1-800-743-cbs. miss something? head to madmoney.cnbc.com. >> high takes .

all week we have been following the jpmorgan story as part of the biotech the next generation story. tonight we have a speculative vaccine developer, nova vac, nvax. they have a proprietary n ark no particular vaccine technology platform that allows them to develop novel vaccines to protect infants, children and the elderly against a

respiratory illness known as a rsv and seasonal and pandemic varieties of the flu. company has an ebola vaccine about to start clinical trials. ebola has allowed nova vax to rally since the beginning of october as i question whether a company can commercialize something needed for compassionate use. the guys are a a long way from having products on the market. they don't have major partnerships either which makes it speculative. still it has potential. let's take a closer look at the president and ceo of novavax. welcome to "mad money." >> thanks for having me on. >> i know the ebola scare in our country and the terrible tragedy in west africa has has people interested in novavax, but it's other vaccines that would probably be much more commercially viable, right? >> that is true. >> tell us which oneses are the ones we should think about

commercially. >> investors focus most on the vaccine for rsv, the largest cause of hospitalization, particularly of children under 1 in the united states. people have been working on a vaccine for 50 years unsuccessfully. we made a breakthrough a few years ago in the way we make the rsv vaccine antigen injected into people. it turns out our antigen stimulates a potent immune response uniquely. we decided, you talked about partners. we made the announcement a couple of years ago that we were ahead of the industry by years at least and that we were not going to partner because it would slow us down. >> i had a flu vaccine. when i got it everyone told me -- my doctors wanted me to get it and everyone told oh me it was the one. a lot of people got the flu who had the vaccine. you are working on something with a greater success rate?

>> yes. we are working on a different flu vaccine that uses these re recome nant nano particles. we can use it in the flu vaccine and hopefully have a potent vaccine that works across multiple strains. >> is that -- i was reading the washington post about how this year's flu vaccine, that they guessed wrong. yours seems like it would eliminate guess work. >> no. there's two ways that the vaccine doesn't match the ak a wall virus that's circulating. one is the way most manufacturers have to change the vaccine to grow up in egg cells. makes it different from the circulating flu virus. ours is made from the actual sequence of the circulating virus. that allows us to have a more closely matched strain. if it's actually a wrong call they make this call in february and tell the manufacturers which

strains to use and if a new strain pops up it starts circulating in the flu season in november or december there is nothing anybody could do about that with current technology. >> i know you're enrolling healthy adultses to test safety and immunogenicity of the seasonal flu. are you able to tell how people are doing, whether they are doing better than others or you have to wait until it concludes. >> you have to wait three, four months before we figure it out. >> i was hoping, like everybody else, that if you had good results because both my kids got felled by the stuff. >> oh no. >> i will do anything to make sure it doesn't happen again. last thing, j & j bought an anti-viral franchise. are there other companies that want to partner though you said you wanted to go it alone that

doesn't fesly mean big pharma isn't interested in being your partner. >> that's true. there are half a dozen large pharma companieses with large franchises. as i mentioned, everybody -- every company with a vaccine research effort has a project on rsv, for instance. we think it will be the biggest selling vaccine in the history of vac ians ss -- vaccine. everybody is interested in it. when we get to the point where we have a product licensed through the fda a we can talk about having marketing partners et cetera. >> last question. ebola obssly during september there was a frenzy here. it's a terrible disease. have the companieses -- have you dropped back on that knowing it's not as pertinent or is it full speed ahead? >> our technology uniquely allows us to make a vaccine more rapidly than any other technology. two years ago when h7 and 9 flu

strains started in china with 50% mortality, we took the gene sequence and turned it in and showed 90% protection. that was a remark able result and published in the new england journal of medicine. we are doing the same thing with ebola. we started with the sequence on september 12. we have now vaccinated four different species showed potent robust immune responses. now are going into what'sle called a nonhuman primate challenge study. we'll have data in a few weeks. >> your company is cutting-edge. thank you, stanley. good to see you, sir. >> thank you very much. >> speculative but you hear we know tech mara a looked speculative but not anymore. do the homework. check the presentation. it's all there. before you make a move. "mad money" is back after the

break. >> announcer: coming up -- on target? it's a $7 billion for target shuttering its doors up north. could buying the stock now help you bring home the bacon or does it have a bull's eye on its back? the

listen to me.

you just don't parachute into a foreign country opening 130 stores at once and expect great results. target did it in canada and it's one of the dumbest moves of all time. this morning target bit the bullet as new ce ork brian cornell, nothing to do with the movement there, decided to close the canadian operations after a staggering $7 billion in canadian dollar losses including $4.5 billion loonies in opening costs and $2.5 billion in opening red ink. that's totally up in smoke. would have been cheaper if target put that $4.5 billion investment into a big pile of cash and lit it on fire a la the shield. that's right. the canadian expansion is one of the most monumental wipe outs of shareholder capital i have seen. the new ceo put an end to it. as he promised.

i struggle to find a similar blunder to oh this fiasco. the ill fated combined british-american attack where 70 oh,000 soldiers parachuted behind german lines in 1944 in a wrong headed move to end world war ii by christmas. they thought they could parachute into canada overnight and make it work. it was a bridge too far, like the terrific movie that chronicled the disaster. between the canadian debacle and the data breach that stung target last year the regime almost crush eded this retailer. nearly destroyed jcpenney to reinvent the retailer. i wasn't a fan of target but i know i made a blunder not putting him on the wall of shame. he should have been inducted by veterans, whatever. it would have been a 100% vote. who believed target could open

the storeses in canada and become profitable. the losseseses were mon mental. i want you to contrast it with nordstrom who moved into canada last year after a great deal of thought by opening a single store in calgary near the end of the year one location. nordstrom will open stores slowly and carefully because management wanted to get canada right. no arrogance there. i stress the importance of bold leadership with companies you might invest in. that's what cornell gave you with the swift decision. he announced target's u.s. sales were up 3% not the 2% wall street was expecting. the determination put to bed one of the most disastrous gambits i have seen and allowed the star of the u.s. to shine through. what do you do with target the stock thousand that the distraction is behind them? you buy it. buy some tomorrow and then some lower. cornell can restore the chain's former greatness.

he's reinventing aisle of aisle making target a destination store for shoppers. we have to feel terrible for the laid off a canadian workers. target set up $70 million canadian dollars support to ensure six weeks of compensation. this is the right november. it seems incongruous to congratulate someone for ending an initiative but congratulationses are in order since cornell did better in the u.s. while they lost fortunes in canada. who knows what they can accomplish under cornell now that canada is closed and the data breach is in the rear are view mirror. target will do better than last year. maybe that's all you need to know. how about gene in florida. >> caller: boo-yah, jim. you nailed it with rite-aid. i bought it at a low five and i'm holding it long. my question is do you feel fire eye is a good product and can stop the hacking with the feds

and set-com. should i hold buy or hold it long? >> thank you on the rite-aid. tom and jerry at my brooklyn store opened my eyes to rite-aid. fire eye, if this stock goes below 30 we should be a buyer. it has a very good like cyber arc, palo als to network an anti- anti-cyber theft issue but they are expensive. dan in florida, please. >> caller: boo-yah, jim. how you doing, sir? >> real good. how about you? >> caller: good. my question was in regards to twitter. i was looking maybe at investing in it. i got scared a little bit. because of the site getting hacked. i wondered if it would have an effect on the stock. plus the second one was costello may be leaving the company. i'm laery on the stock now.

we want to get bigger as it came closer. we're not happy with management. i have made it clear. the stock got hammered. i don't know why. a lot of people say i have had enough of social media including twitter. i urge you to stay in it some. we are not big in it. charitable trusts will get bigger. stocks get cheaper. management could monetize something that's every single person on air has the twitter handle no matter what station. are you telling me twitter can't make money with that? pathetic. how about curtis? >> caller: good evening, jim. >> i'm doing good. how you been? >> caller: doing pretty good, all things considered. hoping for a packers/patriots super bowl. listen, i want to say thank you for all you do for investors across cramerica, first of all. i want to see you feel about

remaining long on microsoft. >> i like that it's in the city where you will see the other super bowl player and not the camp i don't know, which is seattle. second r. sherman under score 25. it has nice yield, nice break up value. even if it doesn't give the intel, you're okay. i think you hit the bull's eye. target is set to go higher. would you pay $300,000 for a life-saving drug? i'm talking to a company with a hefty price tag and my series booiz tech the next generation. i'll see if this is a speed bump or something else. plus forget the snow and ice. a storm is brewing. it's the lightning round and, yes, indeed, it ain't going to be the pack. it's going to be the hawks. stick with cramer.

[container door opening] ♪ what makes it an suv is what you can get into it. ♪ [container door closing] what makes it an nx is what you can get out of it. ♪ introducing the first-ever lexus nx turbo and hybrid. once you go beyond utility there's no going back.

over the weekend we learned shire is shelling out $5.2 billion for pharma. the speculation began last

month. i liked nps for years because it hases drugs that treat diseases that get incentiveses from the government. big pharmas has figured out there is an enormous amount of value created in the orphan drug space. tonight as part of the series i want to circle back to what's considered to be the best orphan drug developer in the universe. biomarin. they develop enzyme replacement therapies for genetic diseases that can often sell for $300,000 a year because the patients and their insurance providers have no alternative. they have multiple drugs including three for different types of mps. a group of disorders that can cause horrific damage at a cellular level and a drug for severe neurological issues and a

disorder that leadses to muscle weakness. it hases the strongest pipeline in the orphan drugs and will get one more late stage drug candidate for a fatal disorder known as duchesne. the offer was created today. they have given us a 45% gain since we spoke to the ceo this september. if you value the company the way shire valued nps it would be worth $22 billion, substantially more than the current cap of $14.4le billion. let's check in with the ceo of biomarin pharmaceutical to find out more. welcome back to "mad money." >> thank you. great to be back. >> okay. j.j. i was on your website today looking at what vimazin can do. it really does impact people's lives in a positive way, making them have normal lives. you increased the guidance. rather dramatically, frankly. is that because you found more patients doctors heard more about it?

how do you increase it with a limited number of patients out there? >> it's because the launch is going better than anticipated around the world. the feedback we are getting from patients about the benefits they are observing with the drug is positive. and we have already identified over 1650 patients with the disease around the world which is basically $600 million worth of business. we believe there are 2,000 to 3,000 patients around the world which would turn it into $800 million to a billion dollar opportunity. it's exciting. >> i want people to understand how important it is. if you scroll down through the site they have a story about a man named derek. derek is now taking a dose once a week. if he had it without you what would his life be like? >> i think unfortunately that case is likely that the disease would continue to slowly

progress. he would become -- the patient would likely over time become nonam nonambulatory, unable to walk, infections and a shortened life expectancy. >> i think that's why the insurance company would be willing to pay your maintenance fees and be much less than they have to maintain otherwise. let's talk about the new -- you have an offer completed today. there ises more to come. this is a controversial drug as i understand it. dmd has other people who are in this including surepta. you made a bold statement which said you thought your data was superior. somehow that's viewed as not being -- but you should talk about it if you have superior data. >> the reason i made a comparison in my presentation was not to make claims that we have a superior drug but to actually set the record straight

that we believe competition has no data to support the claims that would be made to have more effective drugs. the data doesn't support the claim. >> okay. i know some people regard that as mud slinging. to me it sounds empirical. you have bmn 673 for breast cancer. i okay used to you being an orphan drug. that sounds bigger than an orphan drug. >> depends. this product 673 is part of a new class of cancer agents. the indication we are initially going after is a sub segment of breast cancer patients. it's a fraction of a fraction of breast cancer patients. only about 8 to 10% of breast cancer patients have the specific mutation we are going to address. that represents only 20 25,000 patients in the u.s. which turns

this into an orphan indication. >> oh. so in the time since we have been talking it's clear i guess the big companies have recognized that orphan drugs like shire, you pretty much have to have a presence in them. are you willing to stay independent given that i know a lot of the bigger pharma companieses know they have to be bigger in orphan drugs? >> you know, we have been managing the company to grow and stay. we have growing revenues. you know we will soon report 2014 revenues over $700 million. we believe that we'll reach a billion dollarses in revenues in the next two to three years. we have eight molecules in the clinic by the middle of the year. i think this company has staying power. as a major opportunity for growth in the next five years. >> i couldn't agree more. you have taught me a lot about the industry including why i should believe in biomarin.

many of the viewers, some of whom i though personally have made a lot of money in your stock. thank you. good to see you, sir. >> great to see you, jim. >> guys this is a winner. i don't have to go any further. they have so much and they are doing so many special things. biomarin. "mad money" is back after the break. startup-ny. it's working for new york state. already 55 companies are investing over $98 million dollars and creating over 2100 jobs. from long island to all across upstate new york, more businesses are coming to new york. they are paying no property taxes no corporate taxes no sales taxes. and with over 300 locations, and 3.7 million square feet available, there's a place that's right for your business. see if startup-ny can work for you. go to startup.ny.gov.

lightning round is sponsored by td ameritrade. ♪ >> it is time. it is time for the lightning round on cramer's "mad money." . you call and tell me a stock and i tell you whether to buy, sell. i play this sound. are you ready? time for the lightning round on cramer's "mad money." mike in colorado. mike! >> caller: hey, a big boo-yah to you, dr. cramer. >> nice one, mike. how can i help? >> caller: i need to know about century communitieses. i'm down 30% on the stock. do i let it go or stand tall? >> leonard talked about margins that weren't great and people crushed them. they are the best in the industry. when the best gets crushed the speculative get there. give it three days. we'll look at it then.

ken in florida. ken. >> caller: yes, jim. ken from ft. lauderdale. >> what's up? >> caller: thank you for helping us navigate the markets. great job. my call is about front line. do you feel with lower fuel costs front line is due for a rebound? >> we have to be careful. north american tanker raised the dividend and they can do it again. that's where people are storing oil. i looked at the trade as a hedge fund manager and you don't make much money. i won't recommend these stocks. let them come in. pete in idaho. pete. >> caller: jim boo-yah. going to make it as fast as a i can. the five major railroads -- it's been 18 years since they split. probability of them splitting within the next year or two? not worried about the company. thoughts. >> the split, i don't know.

i have to care about the company. that's what i do for a living and i am worried about coal. i wasn't crazy about michael ward's conference call. he's good at cs kprk. norfolk southern had a big run. pacific has fracking and people are worried about that. the rails were up today. let them come in before we do anything. mimi in florida. >> caller: hi jim. a happy and healthy new year. >> same to you. >> caller: the level is amazing. >> thank you. >> caller: let me ex press my sympathy on the passing of your father. i want to tell you how much i admire the bond you shared with your parents. >> oh my yes. absolutely. i will do a special show about pop. all that he taught me. a lot of the guys on the crew knew pop. it's fun to talk about i him. what's up? >> caller: i will look forward to that. so help me here. as mobile eye free falls, is it a buy? >> no. it represents a particular strain of stock that was

terrific when everyone was excited and the market was good. you caught a good trade. then you had to move on. once they break like this you have to wait a long time. now we have to see good earnings. these aren't stocks that generate good earnings. i'm thinking about mobile eye, speaking -- and yes, talking about go pro which were good for a trade. and that ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade.

while we are talking about the next generation of biotech companieses how about a name that soared into the stratosphere but pulled back in the last few weeks. that should give you a good entry point. i'm talking about rcpt. a firm focused on developing immunology drugs. favor biotechs in developing big drug candidates and multiple shots on goal. there is another approach to create tremendous value. that's developing one drug that can treat many different diseases. a pipeline in a product. not unlike what we saw from allergen. rpc-10 # rpc-1063 is in phase three trials for multiple sclerosis and phase two for colitis. as a treatment for multiple sclerosis the data shows the drug is just as efficacious as the m.s. pill glenya which did $2.1 billion in sales. this drug has a shorter half

life leaves the system in days rather than months which gives dock forstor ohs more flex nblt prescribing it. it's put up strong results in the colitis as well. it's being studied for crohn's and could work on other disorders like lupus and soo rye sis -- psoriasis. and there is an unmet need. they did a big $360 million secondary back in november. good entry point giving them a strong balance sheet, $700 million in cash and little debt. the stock climbed but this the past three weeks pulled back $30 from the high including a decline in today's session. are you getting a terrific buying opportunity and one of the best performing biotechses of 2014? let's dig deeper with the president and ce o to find out what's ahead for the country. welcome to "mad money." >> thanks for having me jim. >> from my spies at the

conference you were the best. i'm not kidding. my people said you were the best. one of the reasons they said it is that your drug for multiple sclerosis is on so many different levels better than the standard of care now that they say it could be a 2015 development. is that possible? >> well look. we are excited about the opportunity as pointed out for inflammatory bowel disease. in m.s. there is a high unmet need. you have laid out the fact that we appear to have a better safety profile than jilenia. we are on track to have our phase threes our final registrational program in the 2017 time frame. we would be looking to have the product on the market in the 2018 time frame. >> if the fda looks at data over a year and looks at the outcomes and says we have people who have liver problems from glenirka and

cardiac problems. we saw it with a big drug from bristol-myers. >> certainly those things can happen. our base case now is that we will go through the phase threes and present the data to both the fda as well as the european regulatory authorities for approval in the time frame. we'll stick to the base case in terms of launch timing is. >> how can a drug have so many indications? i have never heard of a drug -- botox did a lot of different things. for diseases that i didn't think were linked, multiple sclerosis, bowel disease, crohn's. how is that possible? >> it's a great question. our drug actually sequesters or locks up what we call auto reactive lymphocytes or blood cells that have gone high wire. auto immune disorders like multiple sclerosis, inflammatory

bowel disease, rheumatoid arthritis and psoriasis, these are inflammatory conditions. if we can control the circulating lymphocytes we can potentially control the inflammation that ends up being the root cause of the different disorders. so for instance in the gut there is very large limbymphlymphoid organs. we can control that and the inflammation. >> i live in new jersey and sellgene is the biggest employer next the merck and they are pulling out. there are drugs similar to the ones you mentioned. do you ever look at what the other guy is doing and say, we shouldn't go there because the other guy has a better franchise than us? >> yeah. we are always looking at the competitive landscape. in multiple sclerosis, for example, we saw a great opportunity for an oral compound in a disease area which has been largely marked by injectables,

interferons and other injectables. the need for unique safe tolerable therapieses is significant in m.s. and inflammatory bowel disease. we look at all of the compound ss that our competitors are developing and try to make sure we are bringing something forward that's unique and has a real opportunity, advantage to impact patients. >> you did that so i presume you don't need a partner, you can keep the rights and you don't -- you're really not -- if someone wanted to buy you, you could stand alone, right? >> look yeah. our intention is to build a sustainable organizeationorganization. we have rp1063 which you have mentioned. we do think of it as a franchise in a bottle. m.s. and inflammatory bowel disease but we are looking at other indications we could go into within this auto immune space. we have inlicensed rp-4046 and

we will continue to build out the pipeline. it ises our intention to build a global organization and build an organization of scale and sustainability. yes, we are happy we have been able to raise a significant amount of capital that will drive us forward. we will establish a partnership, jim, but in that context it's really helping us add to our commercial might and over time we'll build our own infrastructure to really carry ourselves forward. >> you have an exciting situation. people say how can a stock go up 300%? if they listen to what you said they can understands it. the ce o and president of re-septemberre sept re-september -- receptos. >> thanks for having me. >> this is the kind of company that could hit it out of the park. that's how you have to believe in a company that's already gone up 300%. stick with cramer.

(everyone) cheers! glad you made it buddy. thanks for inviting me. thanks again my friends. for everything for all your help. through all life's milestones our trusted advisors are with you every step of the way. congratulations! thanks for helping me plan for my retirement. you should come celebrate with us. i'd be honored. plan for your goals with advisors you know and trust. so you can celebrate today and feel confident about tomorrow. chase. so you can.

all right. listen to this. a convicted rare coin swindler hires a hit man to kill the federal judge and prosecutor who put him away. not one but two episodes of "american greed" tonight. you have one up next and the season premiere at 10:00 p.m. eastern and pacific on cnbc. i like to say there is always a market somewhere. i like to find it for you on "mad money." i'm jim cramer and i will see you tomorrow!

>> narrator: in this episode of "american greed"... they're called the "bling ring," a fast crowd of celebrity wannabes. >> accused of robbing some of hollywood's hottest young stars of jewelry and other items. >> narrator: and now they talk to "american greed." >> our culture in hollywood is extravagant. >> some people might strive to go to medical school. i guess in the l.a. area, young people strive to have rolex watches. >> narrator: but the bling ring steals more than jewelry. >> they weren't primarily motivated by money. they were almost taking pieces of the fame. >> narrator: but first danny pang is a high-rolling financier with a devil-may-care attitude. >> "i don't give a [bleep]"